Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

5.770 -0.150 (-2.53%)
Streaming Delayed Price Updated: 2:47 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Departure of Board Member
From Ardelyx, Inc.
Via GlobeNewswire
Why Ardelyx Stock Soared Today
Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know. 
Via The Motley Fool
Why Shares of Ardelyx Were Down Wednesday
The company's hopes for approval of a drug to treat chronic kidney disease took a hit. 
Via The Motley Fool
Ardelyx to Participate at the Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
5 OTC Stocks With The Potential To Explode In 2024
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms. 
Via Benzinga
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
From Ardelyx, Inc.
Via GlobeNewswire
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
3 Penny Stocks to Buy and Hold for the Next 10 Years
These three penny stocks are the ones to buy and hold through the market conditions and the years to come for returns. 
Via InvestorPlace
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tesla, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Why Ardelyx Stock Popped Today
Ardelyx finally received the long-awaited FDA approval for its chronic kidney disease drug. 
Via The Motley Fool
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Crude Oil Rises Sharply; Ardelyx Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling more than 1% on Wednesday. The Dow traded down 0.70% to 33,760.26 while the NASDAQ fell 1.45% to 13,338.71. The S&P 500 also... 
Via Benzinga
Topics Stocks
Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. 
Via Benzinga
Topics Bankruptcy
Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Ardelyx Inc. (NASDAQ: ARDX) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
Workhorse (WKHS) Stock Jumps on Drone Business Success
Workhorse stock is getting a boost on Wednesday morning after providing WKHS investors with an update on its drone business. 
Via InvestorPlace
FDA Sends ARDX Stock Soaring After Approving Ardelyx’s Kidney Disease Drug
ARDX stock is rallying after the U.S. Food and Drug Administration (FDA) approved Ardelyx's kidney disease treatment. 
Via InvestorPlace
After Initial Rejection, FDA Approves Ardelyx's Kidney Disease-Related Drug
The FDA approved Ardelyx Inc's (NASDAQ: ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on... 
Via Benzinga
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
Additional non-dilutive capital extends runway to support the launch of XPHOZAH® (tenapanor) and continued commercial investment into IBSRELA® (tenapanor) in the U.S. 
From Ardelyx, Inc.
Via GlobeNewswire
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
From Ardelyx, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
From Ardelyx, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.